Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology

Nardi, Aguinaldo Cesar; Reis, Leonardo Oliveira; Zéqui, Stênio de Cássio; Nardozza, Archimedes

doi:10.1590/s1677-55382012000200003

Cited by 19 publications

(23 citation statements)

References 23 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The predominant pathological TNM stage was pT2c (60%), but this was different from previous studies by Freedland et al (11) (pT2a, 34%) and Makarov et al (12) (pT1c, 77%). Our findings are in agreement with those of Nardi et al (13) who reported that patients treated in a public health care institution, as was the case in our study, represent a cohort with specific characteristics such as higher PSA levels, slightly older age, and more advanced disease than patients treated in a private health care institution (13). …”

Section: Discussionsupporting

confidence: 93%

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

The purpose of this study was to investigate the relationship between cyclin D1 expression and clinicopathological parameters in patients with prostate carcinoma. We assessed cyclin D1 expression by conventional immunohistochemistry in 85 patients who underwent radical prostatectomy for prostate carcinoma and 10 normal prostate tissue samples retrieved from autopsies. We measured nuclear immunostaining in the entire tumor area and based the results on the percentage of positive tumor cells. The preoperative prostate-specific antigen (PSA) level was 8.68±5.16 ng/mL (mean±SD). Cyclin D1 staining was positive (cyclin D1 expression in >5% of tumor cells) in 64 cases (75.4%) and negative (cyclin D1 expression in ≤5% of tumor cells) in 21 cases (including 15 cases with no immunostaining). Normal prostate tissues were negative for cyclin D1. Among patients with a high-grade Gleason score (≥7), 86% of patients demonstrated cyclin D1 immunostaining of >5% (P<0.05). In the crude analysis of cyclin D1 expression, the high-grade Gleason score group showed a mean expression of 39.6%, compared to 26.9% in the low-grade Gleason score group (P<0.05). Perineural invasion tended to be associated with cyclin D1 expression (P=0.07), whereas cyclin D1 expression was not associated with PSA levels or other parameters. Our results suggest that high cyclin D1 expression could be a potential marker for tumor aggressiveness.

show abstract

Section: Discussionsupporting

confidence: 93%

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…The Brazilian Society of Urology published in 2012 (Nardi et al, 2012) the profile of patients assisted by public and private institutions in Brazil (10). Around 54% of prostate cancer patients were treated in public institutions, including older men (69 years x 67 years, p<0.001), more African-americans (18.3 vs. 7%, p<0.001), with more advanced disease, higher medium PSA value (10.0 vs. 6.8, p<0.001) and higher incidence of metastatic disease (10.4% vs. 4.3%, p<0.001).…”

Section: Resultsmentioning

confidence: 99%

Prostate cancer in Brazil and Latin America: epidemiology and screening

Tourinho-Barbosa¹,

Pompeo²,

Glina³

2016

Int. braz j urol.

View full text Add to dashboard Cite

Introduction:Prostate cancer is one of the tumors with higher incidence and mortality among men in the World. Epidemiological data are influenced by life expectancy of population, available diagnostic methods, correct collection of data and quality of health services. Screening of the disease is not standardized around the World. Up till now there is no consensus about the risks versus benefits of early detection. There are still missing data about this pathology in Latin America.Objective:to revise current epidemiologic situation and early diagnosis policies of prostate cancer in Brazil and Latin America.Materials and Methods:Medline, Cochrane Library and SciELO databases were reviewed on the subject of epidemiology and screening of prostate cancer. Screening research was performed in websites on national public health organizations and Latin America. Screening recommendations were obtained from those governmental organizations and from Latin American urological societies and compared to the most prominent regulatory agencies and societies of specialists and generalists from around the World.Results:Brazil and Latin America have a special position in relation to incidence and mortality of prostate cancer. In Brazil, it occupies the first position regarding incidence of cancer in men and the second cause of mortality. Central America has the highest rate of mortality of the continent with lower incidence/mortality ratios. Screening recommendations are very distinct, mainly among regulatory organs and urological societies.Conclusion:prostate cancer epidemiology is an important health public topic. Data collection related to incidence and mortality is still precarious, especially in less developed countries. It is necessary to follow-up long term screening studies results in order to conclude its benefits.

show abstract

“…O câncer de próstata foi discutido em dois trabalhos com abordagens diferentes 28,32 . Um dos estudos abordou o atendimento ofertado a homens com neoplasia de próstata em instituições particulares e públicas 28 .…”

Section: Câncer De Próstataunclassified

Acessibilidade da População Negra ao Cuidado Oncológico no Brasil: Revisão Integrativa

Paulista

Assunção

Lima

2020

Rev. Brasileira.De.Cancerologia

View full text Add to dashboard Cite

Introdução: Tem-se apontado a persistência de desigualdades raciais na acessibilidade a bens e serviços de saúde, estando o indivíduo com câncer inserido nesse contexto. Objetivo: Analisar os fatores que impactam a acessibilidade da população negra ao cuidado oncológico no Brasil. Método: Por meio de uma revisão integrativa da literatura, buscaram-se, nas bases PubMed, LILACS e Embase, artigos originais publicados em português, inglês e espanhol sem limite temporal. Resultados: Foram incluídos 13 artigos, analisados a partir do tipo de câncer abordado: câncer de mama, câncer ginecológico, câncer de próstata e câncer de cavidade oral. Conclusão: As desigualdades raciais e socioeconômicas refletem nas ações de acessibilidade ao cuidado oncológico, maioritariamente na detecção precoce. Independentemente do tipo de câncer e das formas de diagnóstico e de tratamento, é inegável a dificuldade do paciente negro aos cuidados oncológicos por razões de natureza social e econômica. Os profissionais de saúde deveriam assegurar o atendimento à população negra ao mesmo nível prestado aos demais grupos sociais para garantir e superar as barreiras de acesso aos bens e serviços de saúde.

show abstract

Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology

Abstract: ARTICLE INFO ___________________________________________ _

Cited by 19 publications

References 23 publications

Cyclin D1 expression in prostate carcinoma

Cyclin D1 expression in prostate carcinoma

Prostate cancer in Brazil and Latin America: epidemiology and screening

Acessibilidade da População Negra ao Cuidado Oncológico no Brasil: Revisão Integrativa

Contact Info

Product

Resources

About

Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology

Abstract: ARTICLE INFO _______________________________________________________________ _____________________

Cited by 19 publications

References 23 publications

Cyclin D1 expression in prostate carcinoma

Cyclin D1 expression in prostate carcinoma

Prostate cancer in Brazil and Latin America: epidemiology and screening

Acessibilidade da População Negra ao Cuidado Oncológico no Brasil: Revisão Integrativa

Contact Info

Product

Resources

About

Abstract: ARTICLE INFO ___________________________________________ _